A retrospective evaluation of the steroid sparing effects of oral mycophenolate mofetil (MMF) as an adjunct immunosuppressant for the treatment of canine pemphigus foliaceus

2021 ◽  
Author(s):  
Andhika Putra ◽  
Michaela Austel ◽  
Frane Banovic
Keyword(s):  
Mycophenolate Mofetil ◽  
Pemphigus Foliaceus ◽  
Retrospective Evaluation ◽  
Steroid Sparing

Mycophenolate Mofetil as an Adjuvant Therapy for Classic and Endemic Pemphigus Foliaceus

2005 ◽  
Vol 32 (7) ◽  
pp. 574-580 ◽  
Author(s):  
Milka Yuri Kawashita ◽  
Katia Tsai ◽  
Valéria Aoki ◽  
Claudia Giuli Santi ◽  
Celina Wakisaka Maruta ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Adjuvant Therapy ◽  
Pemphigus Foliaceus ◽  
Endemic Pemphigus Foliaceus

scholarly journals Mycophenolate Mofetil for the Treatment of Autoimmune Hepatitis in Patients Refractory to Standard Therapy

2004 ◽  
Vol 18 (5) ◽  
pp. 321-326 ◽  
Author(s):  
Shane M Devlin ◽  
Mark G Swain ◽  
Stefan J Urbanski ◽  
Kelly W Burak
Keyword(s):  
Mycophenolate Mofetil ◽  
Autoimmune Hepatitis ◽  
Alanine Aminotransferase ◽  
Standard Therapy ◽  
Conventional Treatment ◽  
Case Series ◽  
Therapeutic Options ◽  
Sparing Effect ◽  
Histological Remission ◽  
Steroid Sparing

There are limited therapeutic options available for patients with autoimmune hepatitis in whom conventional treatment fails. A case series of five patients unresponsive to or unable to take azathioprine, 6-mercaptopurine or corticosteroids who were treated with mycophenolate mofetil (MMF) is reported. While on MMF, alanine aminotransferase normalized or remained normal in all patients. MMF had a steroid-sparing effect and histological remission was demonstrated in one patient after seven months of MMF. One patient experienced an uncomplicated episode of pyelonephritis. In conclusion, MMF can effectively induce and maintain remission in refractory autoimmune hepatitis patients.

scholarly journals Mycophenolate mofetil as steroid-sparing treatment for elderly patients with giant cell arteritis: report of three cases

2012 ◽  
Vol 24 (3) ◽  
pp. 273-277 ◽  
Author(s):  
Savino Sciascia ◽  
Doloretta Piras ◽  
Simone Baldovino ◽  
Alessandra Russo ◽  
Carla Naretto ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Elderly Patients ◽  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Steroid Sparing

Mycophenolate Mofetil Therapy Is a Steroid Sparing In Childhood and Young Adult Chronic ITP and Evans Syndrome.

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 1441-1441
Author(s):  
Zaher Naji ◽  
Madhvi Rajpurkar ◽  
Sureyya Savasan ◽  
Roland Chu ◽  
Meera Chitlur ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Side Effects ◽  
Bleeding Complications ◽  
Severe Bleeding ◽  
Evans Syndrome ◽  
Corticosteroid Administration ◽  
Chronic Itp ◽  
Life Threatening ◽  
The Mean ◽  
Steroid Sparing

Abstract Abstract 1441 Chronic ITP and Evans syndrome are diseases characterized by autoantibody formation with resultant destruction of platelets or both platelets and red blood cells on neutrophils, respectively. Affected patients are at risk of life threatening bleeding complications and/or life threatening anemia. Conventional therapies are often ineffective or transiently effective and have significant toxicity. One of the most commonly used therapeutic strategies employs chronic corticosteroid administration with the attendant weight gain, hypertension, hyperglycemia, bone loss, infection risk, mood changes and protean other undesirable side effects. Mycophenolate Mofetil (MMF) is an immunosuppressive agent with a favorable side effect profile. It is converted to the active metabolite, mycophenolic acid, and interferes with purine metabolism in T-lymphocytes, effectively killing many of these cells and down-regulating autoimmune phenomena. With approval of our local IRB /HIC we retrospectively reviewed the charts of 11 chronic ITP/Evans syndrome patients who had received MMF, all such patients treated at a large urban Children's Hospital. Clinical variables included age, sex, duration of disease, steroid use, IVIG use, Anti-D use, platelet counts, hemoglobin concentrations and reticulocyte percentages. These data were analyzed using paired t-tests, one-sample t-test and descriptive statistics. The 11 patients ranged in age from 9–22 years old, with a mean age of 15 years. The mean time from diagnosis of disease was 41.8 months with a range of 6–95 months. There were 5 female subjects, 6 Evans syndrome patients and 5 with chronic ITP alone. The median platelet count over the 6 months prior to MMF was 70×109/L, (18-223), with a median of 90×109/L with (27-145) during the first 6 months of MMF therapy (p=0.4). In the Evans syndrome group, the mean hemoglobin prior to MMF was 10.9 g/dL, (9.1-14.6), with a mean of 12.1 g/dL, (6.9-16.7) on MMF (p=0.54). Similarly, the mean reticulocyte percentage was 2.7%, (0.5-14) prior to MMF, with a mean of 2.3%, (0.3-8.9) during MMF therapy. The mean total dose of steroids used in the 6 months prior to MMF was 84.2 mg/kg (prednisone equivalent), (11.2-170), compared to 62.2 mg/kg, (0-193.8) on MMF. 9 of 11 patients had reductions in steroid requirement by an average of 49.3% (p=0.0013). During the first 6 months of MMF both IVIG and anti-D usage decreased from total doses for the entire group of 17 and 3 doses to 8 and 1 dose, respectively. None of the patients experienced severe bleeding episodes or side effects more serious than a transient rash while on MMF. These data suggest that MMF may have a role as a steroid sparing therapy in the treatment of chronic ITP and Evans syndrome. Disclosures: Off Label Use: mycophenolate mofetil for ITP Evans syndrome.

Steroid-Sparing Effect Of Mycophenolate Mofetil In Pulmonary Sarcoidosis

2010 ◽  
Author(s):  
Preetam Jolepalem ◽  
Nevins W. Todd ◽  
Edward J. Britt ◽  
Michael Terrin ◽  
Carla Peterman ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Pulmonary Sarcoidosis ◽  
Sparing Effect ◽  
Steroid Sparing

Mycophenolate Mofetil May Allow Cyclosporine and Steroid Sparing in De Novo Heart Transplant Patients

2007 ◽  
Vol 83 (5) ◽  
pp. 570-576 ◽  
Author(s):  
Iman M. Hamour ◽  
Haifa S. Lyster ◽  
Margaret M. Burke ◽  
Marlene L. Rose ◽  
Nicholas R. Banner
Keyword(s):  
Mycophenolate Mofetil ◽  
Heart Transplant ◽  
De Novo ◽  
Transplant Patients ◽  
Steroid Sparing
Sign in / Sign up

Export Citation Format

Share Document